Starling Oncology, Inc. - 8-K Filing

Starling Oncology issues investor presentation highlighting FY26 revenue guidance of $650M–$660M and 3Q26 results showing 24% YoY revenue growth. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)

SEC EDGAR · November 12, 2026, 13:03 UTC

Tickers: $DFPH

Read the full article at SEC EDGAR

Part of the story Walker & Dunlop, Inc. - 8-K Filing (3 articles)

More Regulatory news

FILANA THERAPEUTICS, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 13:18 UTC
RUM Group Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:17 UTC
Theriva Biologics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SeaStar Medical Holding Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Avalyn Pharma Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SES AI Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Data443 Risk Mitigation, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
TRUSTMARK CORP - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SUBURBAN PROPANE PARTNERS LP - 8-K Filing SEC EDGAR · November 12, 2026, 13:14 UTC
MeiraGTx Holdings plc - 10-Q Filing SEC EDGAR · November 12, 2026, 13:13 UTC